Nucleoside reverse transcriptase inhibitors (NRTIs) represent a novel immunomodulatory therapeutic approach for Alzheimer's disease (AD) that targets multiple pathological pathways simultaneously. Originally developed for HIV treatment, NRTIs such as lamivudine, emtricitabine, and kamuvudine-9 have demonstrated immunomodulatory properties that extend beyond their antiviral effects, making them candidate disease-modifying agents for neurodegenerative conditionshussain2024 2024, Targeting Neuroinflammation in Alzheimer.
The therapeutic rationale for NRTIs in AD rests on three interconnected mechanisms: (1) inhibition of the NLRP3 inflammasome, a key driver of neuroinflammation; (2) suppression of type-I interferon signaling that is chronically elevated in AD brain; and (3) inhibition of endogenous retroviral element activation that may contribute to chronic neuroinflammation. This multi-target approach addresses the complex interplay between neuroinflammation, protein pathology, and immune dysregulation that characterizes AD pathogenesisbrouwers2020 2020, Nucleoside reverse transcriptase inhibitors and the role of endogenous retrov....
The NLRP3 inflammasome is a critical component of the innate immune system that plays a pivotal role in AD pathogenesis. In the AD brain, the NLRP3 inflammasome is activated by multiple stimuli including amyloid-beta plaques, tau pathology, and damage-associated molecular patterns (DAMPs)heneka2015 2015, Neuroinflammation in Alzheimer.
Evidence for NLRP3 activation in AD:
Multiple studies have demonstrated elevated NLRP3 inflammasome components in AD brain tissuechoi2021 2021, NLRP3 inflammasome activation in Alzheimer, and genetic studies link NLRP3 variants to AD riskkhan2022 2022, Inflammasome activation in Alzheimer. The inflammasome drives pathology through caspase-1 activation and subsequent cytokine releasejha2017 2017, NLRP3 inflammasome: Central regulator in neurodegenerative diseases.
Mechanism of NRTI Action:
Therapeutic Impact: The inhibition of NLRP3 inflammasome activity by NRTIs addresses a central mechanism driving disease progression. By reducing chronic neuroinflammation, NRTIs may slow the accumulation of both amyloid and tau pathology, potentially providing disease-modifying effects rather than merely symptomatic reliefli2023 2023, Targeting NLRP3 inflammasome in Alzheimer. Clinical targeting of the NLRP3 inflammasome for AD treatment has shown progress and challengeswang2023 2023, Targeting the NLRP3 inflammasome for Alzheimer.
Type-I interferons (IFN-α, IFN-β) are cytokines that play essential roles in antiviral defense, but chronic elevation of type-I interferon signaling has been implicated in AD pathogenesismain2020 2020, Type-I interferon responses are upregulated in Alzheimer. Research has shown that type-I interferon signaling creates a reversible neuronal hypometabolic state in ADswarup2022 2022, Type I interferon signaling drives a reversible neuronal hypometabolic state ..., and patients with interferonopathies show increased neurodegenerative disease riskzhao2022 2022, Type I interferonopathies in neurodegenerative disease.
Evidence for Type-I Interferon Dysregulation in AD:
NRTI Mechanism in Interferon Modulation:
The proposed mechanism by which NRTIs modulate type-I interferon signaling involves:
Human endogenous retroviruses (HERVs) are remnants of ancient retroviral integrations that comprise approximately 8% of the human genome. Under certain conditions, including aging and disease, HERVs can become transcriptionally active and produce proteins that may contribute to neurodegenerationdembny2020 2020, Human endogenous retrovirus HERV-K(HML-2) activity is detected in AD but not .... The HERV-K envelope protein has emerged as a potential therapeutic targethaque2023 2023, HERV-K envelope protein in Alzheimer, and endogenous retroviral elements play a significant role in neurodegenerative disease pathogenesisjohnson2023 2023, Endogenous retroviral elements in neurodegenerative disease: Implications for....
HERVs and Alzheimer's Disease:
NRTI Action on HERVs:
Kamuvudine-9 (K-9), a second-generation NRTI, has been the subject of preclinical investigations demonstrating immunomodulatory effects relevant to AD. A systematic review has examined the potential for repurposing NRTIs in ADaye2022 2022, Repurposing Nucleoside Reverse Transcriptase Inhibitors for Alzheimer, and research on NRTI-induced immunomodulation in neurodegenerative disease models has shown promisesandhu2023 2023, NRTI-induced immunomodulation in neurodegenerative disease models.
Key Findings:
Research on other NRTIs has provided supporting evidence for immunomodulation in neurodegenerative contextspatel2023 2023, Evaluating NRTI therapy in Alzheimer:
| NRTI | Model System | Key Findings | Reference |
|---|---|---|---|
| Lamivudine | Amyloid-beta treated neurons | Reduced inflammatory markers | liu2010 2010, Amyloid-β-induced synaptic dysfunction through NMDA receptors |
| Emtricitabine | Microglial cultures | Shifted to anti-inflammatory phenotype | tang2018 2018, Differential Roles of M1 and M2 Microglia in Neurodegeneration |
| Azidothymidine | Animal models | Reduced neuroinflammation | becker2018 2018, What does proton pump inhibition have to do with Alzheimer |
A Phase 1 clinical trial (NCT04500847) at Butler Hospital investigated the repurposing of NRTIs for AD treatment:
Trial Design:
Outcome Measures:
Rationale: The trial tested the hypothesis that antiviral doses of NRTIs would suppress HERV activation and reduce type-I interferon-driven neuroinflammation in AD patientsgoldman2021 2021, Chronic viral infections and neurodegeneration: What can we learn from the NR....
Additional clinical investigations are exploring NRTI-based approaches:
NRTIs offer several advantages as potential AD therapeuticssingh2024 2024, Immunomodulatory effects of nucleoside analog drugs in neuroinflammation:
| Approach | Target | Stage | Advantages | Limitations |
|---|---|---|---|---|
| NRTIs | NLRP3, HERV, IFN | Phase 1 | Multi-target, established safety | Limited CNS penetration for some |
| Anti-IL-1β | IL-1β | Phase 2 | Direct cytokine blockade | Single target |
| TREM2 agonists | Microglial activation | Phase 2 | Enhances phagocytosis | Single target |
| JAK inhibitors | JAK/STAT signaling | Phase 1 | Broad immunomodulation | Immunosuppression risk |
Microglial activation in AD has been reviewed extensivelymccann2023 2023, The evolving understanding of microglial activation in Alzheimer, and the role of bacterial lipopolysaccharide in AD immunopathogenesis has been documentedmorris2018 2018, The role of microbial translocation and bacterial lipopolysaccharide in the i....
Potential biomarkers for identifying patients who may benefit from NRTI therapy include:
Microglial activation can be targeted through therapeutic interventionagarwal2020 2020, Microglial activation in Alzheimer, and microglia-neuron communication plays a critical role in AD progression from inflammation to synaptic losschen2021 2021, Microglia-Neuron communication in Alzheimer.